Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on September 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E Lowenthal, the President and CEO of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on September 10, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions, each involving 50,000 shares, at weighted average prices of $11.4973 and $11.4982, respectively.
• The price range for the sales was between $11.28 and $11.82.
• Following the transactions, Lowenthal directly owns 4,315,313 shares.
• Lowenthal also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and his spouse's trust.
• He disclaims beneficial ownership of shares held by his spouse's trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock sales by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

Sales by company insiders are a common occurrence and are often viewed in the context of the insider's overall holdings and the reasons for the sale (e.g., diversification, tax planning). The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on current market information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates